Lead Product(s) : Verteporfin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System
Details : Verteporfin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 04, 2025
Lead Product(s) : Verteporfin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Verteporfin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Modulight, Inc. | National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Verteporfin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 12, 2024
Lead Product(s) : Verteporfin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Modulight, Inc. | National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Verteporfin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
Details : Verteporfin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 01, 2017
Lead Product(s) : Verteporfin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Verteporfin
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Verteporfin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 20, 2016
Lead Product(s) : Verteporfin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Verteporfin
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Photodynamic Therapy for the Treatment of Vertebral Metastases
Details : Visudyne is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasm Metastasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 08, 2015
Lead Product(s) : Verteporfin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Verteporfin
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Verteporfin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Central Serous Chorioretinopathy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 29, 2011
Lead Product(s) : Verteporfin
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
